1. HBW Insight
  2. >>Geography
  3. >>Asia
  4. >>China

Haleon Talks Up China Strength As Investment Grows

 
• By Tom Gallen

Haleon highlighted consistent market share gains in China as it reported third-quarter results.

(Shutterstock)

A double-digit gain in China helped Haleon deliver mid-single-digit sales growth in the third quarter.

Haleon’s second-largest market in terms of sales after the US, China recorded organic growth of 13% in Q3 reflecting the continued strength of calcium supplement Caltrate and systemic pain reliver...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Haleon Completes Deal To Grow Stake In China JV

 
• By Tom Gallen

Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.

Self-Care ‘Essential’ To Universal Health Coverage, Stress Asia Pacific Health Agencies

 
• By David Ridley

APAC health agencies such as WHO and Thailand's FDA are on board with the self-care agenda, and see it as crucial to achieving universal health coverage.

Haleon Talks Up China Strength As Investment Grows

 
• By Tom Gallen

Haleon highlighted consistent market share gains in China as it reported third-quarter results.

Haleon Strengthens Control Of China JV, Agrees Option To Buy

 
• By Tom Gallen

Joint venture business which markets Haleon's OTC drug brands in China will soon be 88% owned by the UK-based firm.

More from Wellness

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By Tom Gallen

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

Time’s Up For Time-Line Mitopure Supplement Marketer’s Aging Claims In NAD Review

 
• By Malcolm Spicer

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Kennedy’s Balancing Act: Push MAHA, Trim Regs

 
• By Malcolm Spicer

Same-day announcements of RFIs from HHS secretary cover nutrient review process for infant formula and Kennedy’s “10-to-1 deregulatory policy” as part of president’s “broader federal effort to reduce regulatory burdens and increase transparency.”